Work

Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry‐Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO)

Year: 2025
Type: article
Study design: Observational Study
Abstract: The coronavirus disease 2019 (COVID-19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioning regimens, despite limited data on the clinical impact. The Italian Group for Bone Marrow Transplantation (GITMO) conducted a registry-based study involving 3492 patients who underwent allo-HSCT between March 2018 and September 2021. The cryopreserved cohort (n = 976) included patients who received cryopreserved grafts during the pandemic and was compared to the historical cohort (n = 2516). Graft cryopreservation was associated with a lower day 30 incidence of neutrophil and platelet engraftment (adjusted sHR = 0.8 and 0.7, p = 0.031 and p < 0.001, respectively) and delayed hematopoietic recovery. However, primary graft failure rates at day +30 were similar in the cryo and historical cohort (4% vs. 5%, respectively; p = 0.337), also after adjustment (RR = 1.19, p = 0.518). Day 100 incidence of grade II-IV acute GVHD was comparable between the two groups (adjusted sHR = 1.2, p = 0.194). Regarding chronic GVHD incidence, we found that it was higher in patients aged < 18 years in the cryo group (adjusted sHR = 3.9, p = 0.002), but lower in those aged 18-55 years (adjusted sHR = 0.7, p = 0.008). Cumulative incidence of relapse did not differ between historical and cryo cohort (adjusted sHR 1.0. p = 0.943), as well as non-relapse mortality (adjusted sHR 1.1, p = 0.196) and relapse-free survival (adjusted sHR = 1.1, p = 0.197). However, a shorter overall survival was observed in the cryopreserved group (adjusted HR = 1.2, p = 0.038). Transplant centers should carefully balance the benefits and drawbacks of cryopreservation in allo-HSCT.
Institutions: University of Pavia, Policlinico San Matteo Fondazione, Università Cattolica del Sacro Cuore, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Azienda Ospedaliero-Universitaria Careggi, Marche Polytechnic University, Ospedale Policlinico San Martino, Ospedale di Bolzano, IRCCS Humanitas Research Hospital, Azienda USL di Pescara, Azienda sanitaria universitaria Friuli Centrale, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Milano-Bicocca, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, University of Milan, ASST Fatebenefratelli Sacco, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Ospedale Vincenzo Cervello, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale A. Perrino, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale dell' Angelo, Ospedale San Bortolo, Policlinico Umberto I, Sapienza University of Rome, Ospedale Regina Margherita, University of Turin, Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card. G. Panico", AOU San Giovanni di Dio e Ruggi d'Aragona, University of Palermo, Guglielmo da Saliceto Hospital, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Ospedale Antonio Cardarelli, Azienda Ospedaliera Universitaria Senese, University of Padua, Azienda Ospedale - Università Padova, Policlinico Universitario di Catania, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", Istituto Giannina Gaslini, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Azienda Ospedaliera S.Giuseppe Moscati, Meyer Children's Hospital, Federico II University Hospital, University of Naples Federico II, Ospedale Papa Giovanni XXIII, Azienda ospedaliera "Bianchi-Melacrino-Morelli"
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,450
OpenAlex ID: W4410947425
FWCI: 3.114
Cites: 30
Cited by: 5
Related to: 10